33.24 USD
▲-1.38+2.50%
盘后 32.36 -0.22%
2026-08-03
市值
$1.69B
市盈率
—
EPS
-0.55
股息率
—
52 周区间
27.56 – 40.72
成交量
576.25K
Beta
0.74
目标价
63.58
52W 低 27.5652W 高 40.72
价格走势
公司简介
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase ...